Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sosei Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sosei Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sosei Group's earnings are expected to grow significantly at over 20% yearly.
Sosei Group's revenue is expected to grow by 17.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sosei Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Shinichi Tamura is the founder of Sosei Co. Ltd. and has been its President and Representative Executive Officer since November 2006. Mr. Tamura is the Founder of Sosei Group Corporation and has been its Executive Chairman since June 24, 2016 and has been its Representative Executive Officer since June 2005. He has been President and CEO of Sosei Group since January 1, 2019. He served as the Group Chairman, Chief Executive Officer and President of Sosei Group Corporation since June 1990 until June 24, 2016. Mr. Tamura advised various companies e.g. Genentech, GenPharm, Geron, IDEC, Pharmacyclics, Vernalis among others. Prior to that, he worked for Fujisawa Pharmaceutical Co., Ltd. at various positions in Planning. Mr. Tamura serves as a Director of Sosei Co. Ltd. He is a Tokyo University graduate with M.S. in Biochemistry and a major in Cultural Anthropology.
Insufficient data for Shinichi to compare compensation growth.
Shinichi's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Sosei Group management team is less than 2 years, this suggests a new team.
Vice President of Corporate Communication Department
Group Head of Human Resources
Executive Officer & Executive VP
Chief Business Officer of Business Development
Senior VP & Head of Drug Discovery
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Sosei Group board of directors is less than 3 years, this suggests a new board.
Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler, Utibron/Neohaler, Seebri/Breezhaler, and Seebri/Neohaler for the treatment of chronic obstructive pulmonary disease (COPD); NorLevo0.75mg, an emergency contraceptive; and ORAVI, an Oropharyngeal candidiasis. The company’s product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors; AZD4635 which is also in Phase 1b/2 clinical study in combination with MEDI9447 (an anti-CD73 antibody developed by MedImmune) for the treatment of non-small cell lung cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer’s disease; and dual M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer’s disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company is developing biopharmaceuticals for the treatment of Alzheimer's disease, cancer, metabolic diseases, and other indications. The company has a strategic collaboration with Kymab and PeptiDream Inc. Sosei Group Corporation was founded in 1990 and is headquartered in Tokyo, Japan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.